(Q43881207)

English

Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device

scientific article published in January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

B-cell non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hillard M. Lazarus

6

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Willem J van Heeckeren

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Jennifer Vollweiler

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Pingfu Fu

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Brenda W Cooper

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Howard Meyerson

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Alexandra Simic

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Mary J Laughlin

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Stanton L Gerson

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Omer N Koç

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

132

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

42-55

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05827.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2005.05827.X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43881207&oldid=2104123636"